Aiding in better digestion to give you less gas, bloating, and discomfort
PloS one , 16 (3), e0247307
Indications of an ongoing shift within healthcare and society more broadly, which include the American Medical Associations recognition of obesity as a disease in 2013, signal a trend towards a more nuanced understanding of the multifactorial nature of the disease, reducing blame and stigmatization and opening doors for greater investment in therapy, including new medications like GLP-1 agonists
Standard starting doses First-time users: Men: Start with 1mg Women: Start with 0.5-0.75mg Assess tolerance and response Adjust after 1-2 trials Don't start high (unnecessary side effects ) Dose progression strategy: Why start low: Nausea common at higher doses (40-60%) Individual sensitivity varies widely Some respond strongly to low doses Can always increase (can't undo high dose) Better to build up than start too high Finding your optimal dose: Use lowest dose that produces desired effect Balance efficacy vs side effects Track each trial (dose, timing, response, sides) Most settle on one consistent dose Some vary based on situation See PT-141 for men nasal spray guide for detailed protocols
Based on Phase 2 trial protocols by Eli Lilly, initiation was typically at 2 mg once weekly via subcutaneous injection, with gradual dose escalation thereafter
